Drugs / rhACE2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04287686 | Feb → Apr 2020 | COVID-19 | The First Affiliated Hospital of Guangzhou Medical University | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhACE2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04287686 ↗ |
| Known as | Recombinant human angiotensin-converting enzyme 2 | “Recombinant human angiotensin-converting enzyme 2 (rhACE2)” NCT04287686 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant human angiotensin-converting enzyme 2 (rhACE2)” NCT04287686 ↗ |
| Route | Intravenous | “In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.” NCT04287686 ↗ |